Vimarsana
Biggest News Aggregation in the World

Page 47 - Maxlinear Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Maxlinear Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Maxlinear Inc Today - Breaking & Trending Today

China slows down reviews of M&As involving US companies: report - Vimarsana News

China slows down reviews of M&As involving US companies: report

The deals still under review include Intel's $5.2b takeover of Tower Semiconductor.

Report: China increasingly uses merger reviews to make demands of US companies - Vimarsana News

Report: China increasingly uses merger reviews to make demands of US companies

China demands for access to products could put US firms in "impossible position."

China's new tech weapon: Dragging its feet on global merger approvals - Vimarsana News

China's new tech weapon: Dragging its feet on global merger approvals

China has been increasingly leveraging its merger-review process and antimonopoly rules to advance its national political and economic goals.

Moody Aldrich Partners LLC Sells 31,732 Shares of MaxLinear, Inc. (NYSE:MXL) - Vimarsana News

Moody Aldrich Partners LLC Sells 31,732 Shares of MaxLinear, Inc. (NYSE:MXL)

Moody Aldrich Partners LLC trimmed its position in MaxLinear, Inc. (NYSE:MXL – Get Rating) by 46.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 36,571 shares of the semiconductor company’s stock after selling 31,732 shares during the quarter. Moody Aldrich Partners LLC’s holdings […]

Source: wkrb13.com
Wells Fargo & Company Reaffirms "Equal Weight" Rating for Fate Therapeutics (NASDAQ:FATE) - Vimarsana News

Wells Fargo & Company Reaffirms "Equal Weight" Rating for Fate Therapeutics (NASDAQ:FATE)

MaxLinear, Inc. (NYSE:MXL – Get Rating) has been given a consensus rating of “Moderate Buy” by the ten ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month price target […]